Clinical trial
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety…
NCT00000812 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000812 |
|---|---|
| Title | A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection |
| Official title | A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 36 |
| Completion | Jul 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 28, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: